John F Valentine MD
Inflammatory Bowel Disease
Professor, Internal Medicine, University of Utah School of Medicine
Join to View Full Profile
50 N Medical Dr# 4R118Salt Lake City, UT 84132
Phone+1 801-581-7802
Fax+1 801-581-7476
Dr. Valentine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Valentine is a gastroenterologist in Salt Lake City, UT and is affiliated with multiple hospitals in the area, including University of Utah Health and Veterans Affairs Salt Lake City Health Care System. He received his medical degree from University of Texas Medical School and has been in practice 29 years. He specializes in inflammatory bowel disease and is experienced in inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
Education & Training
University of FloridaFellowship, Gastroenterology, 1988 - 1991
Virginia Commonwealth University Health SystemInternship, Internal Medicine, 1985 - 1986
McGovern Medical School at UTHealthClass of 1985
Certifications & Licensure
FL State Medical License 1989 - 2026
UT State Medical License 2011 - 2026
ID State Medical License 2021 - 2025
NV State Medical License 2021 - 2025
WY State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (AGAF) American Gastroenterological Association, 2012
Clinical Trials
- Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease Start of enrollment: 2024 Apr 18
Roles: Principal Investigator
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) Start of enrollment: 2024 Jun 12
Roles: Principal Investigator
Publications & Presentations
PubMed
- A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.Silvio Danese, Michael E Rothenberg, Jeremy J Lim, Han Ting Ding, Jacqueline M McBride
Clinical Gastroenterology and Hepatology. 2024-12-16 - 1 citationsIncreased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn's Disease.Marina Chulkina, Christina Rohmer, Steven McAninch, Ronaldo P Panganiban, Romain Villéger
Journal of Crohn's & Colitis. 2024-08-06 - 24 citationsVedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, Corey A Siegel, Douglas C Wolf
Clinical Gastroenterology and Hepatology. 2024-07-01
Grant Support
- Food &Drug Administration (FDA) And Mesc/Dauphin Island SEA LAB CollaborationFood And Drug Administration2011
- FDA And Mesc/Dauphin Island SEA LAB CollaborationFood And Drug Administration2009
- Basic Research Training In Gastroenterology &HepatologyNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2004
- 5asa Regulation Of Mnsod In Intestinal CellsNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2002
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
